Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL® adjuvant

Vaccine

Volumn 20, Issue 27-28, 2002, Pages 3292-3303

  Skeiky, Yasir A W ^a   Coler, Rhea N ^b   Brannon, Mark ^a   Stromberg, Erika ^a   Greeson, Kay ^b   Thomas Crane, R ^a   Campos Neto, Antonio ^b   Reed, Steven G ^a,b  

^a GLAXOSMITHKLINE   (United States)

^b INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Leishmania; MPL; Recombinant polyprotein

Indexed keywords

ANTIGEN; EPITOPE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; LEISHMANIA VACCINE; PHOSPHORYL LIPID A; RECOMBINANT VACCINE; SQUALENE;

ADJUVANT THERAPY; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LYSATE; CONTROLLED STUDY; DRUG EFFICACY; EVALUATION; FEASIBILITY STUDY; FEMALE; GENETIC CODE; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; LEISHMANIA MAJOR; MAJOR HISTOCOMPATIBILITY COMPLEX; MODEL; MOUSE; NONHUMAN; OPEN READING FRAME; PARASITOSIS; POPULATION; PRIORITY JOURNAL; PROTECTION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; DNA, PROTOZOAN; FEMALE; HUMANS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LIPID A; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; OPEN READING FRAMES; PROTOZOAN VACCINES; SQUALENE; VACCINES, SYNTHETIC;

EID: 0037055963     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00302-X     Document Type: Article

References (37)

1. Agostoni C., Dorigoni N., Malfitano A., Caggese L., Marchetti S., Corona S.G.et al. Mediterranean leishmaniasis in HIV-infected patients: epidemiological, clinical, and diagnostic features of 22 cases. Infection. 26:1998;93-99.
2. Dedet J.P., Pratlong F. Leishmania, Trypanosoma and monoxenous trypanosomatids as emerging opportunistic agents. J. Eukaryot. Microbiol. 47:2000;37-39.
3. Magill A.J. Epidemiology of the leishmaniases. Dermatol. Clin. 13:1995;505-523.
4. Murray H.W. Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDS. 13:1999;459-465.
5. Webb J.R., Campos-Neto A., Ovendale P., Martin T.I., Stromberg E.J., Badaro J.et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 66:1998;3279-3289.
6. Webb J.R., Kaufman D., Campos-Neto A., Reed S.G. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 157:1996;5034-5041.
7. Skeiky Y.A.W., Guderian J.A., Benson D.R., Bacelar O., Carvalho E.M., Kubin M.et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J. Exp. Med. 181:1995;1527.
8. Skeiky Y.A.W., Kennedy M., Kaufman D., Borges M.M., Guderian J.A., Scholler J.K.et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol. 161:1998;6171-6179.
9. Skeiky Y.A.W., Benson D.R., Guderian J.A., Whittle J.A., Bacelar O., Carvalho E.M.et al. Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect. Immun. 63:1995;4105-4114.
10. Campos-Neto A., Porrozzi R., Greeson K., Coler R.N., Webb J.R., Skeiky Y.A.W.et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect. Immun. 9:2001;4103-4108.
11. Borges M.M., Campos-Neto A., Sleath P., Grabstein K.H., Morrisey P.J., Skeiky Y.A.W.et al. Potent stimulation of the innate immune system by a Leishmania brasiliensis recombinant protein. Infect. Immun. 69:2001;5270-5277.
12. Probst P., Skeiky Y.A.W., Steeves M., Gervassi A., Grabstein K.H., Reed S.G.et al. A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur. J. Immunol. 27:1997;2634.
13. Skeiky Y.A.W., Ovendale P.J., Jen S., Alderson M.R., Dillon D.C., Smith S.C.et al. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J. Immunol. 165:2000;7140-7149.
14. Campos-Neto A., Ovendale P.J., Bement T., Koppi T.A., Fanslow W.C., Rossi M.A.et al. CD40 ligand is not essential for the development of cell-mediated immunity and resistance to Mycobacterium tuberculosis. J. Immunol. 160:1998;2037-2041.
15. Campos-Neto A., Webb J.R., Greeson K., Coler R.N., Skeiky Y.A., Reed S.G. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect. Immun. 70:2002;2828-2836.
16. Mendez S., Gurunathan S., Kamhawi S., Belkaid Y., Moga M.A., Skeiky Y.A.et al. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose intradermal challenge. J. Immunol. 166:2001;5122-5128.
17. Stobie L., Gurunathan S., Prussin C., Sacks D.L., Glaichenhaus N., Wu C.Y.et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc. Natl. Acad. Sci. U.S.A. 97:2000;8427-8432.
18. Ramsay A.J., Kent S.J., Strugnell R.A., Suhrbier A., Thomson S.A., Ramshaw I.A. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunol. Rev. 171:1999;27-44.
19. Suhrbier A. Multi-epitope DNA vaccines. Immunol. Cell Biol. 75:1997;402-408.
20. Ward S.M., Macnaughto T.B., Gowans E.J. Development and characterisation of recombinant hepatitis delta virus-like particles. Virus Genes. 23:2001;97-104.
21. Le T.T., Drane D., Malliaros J., Cox J.C., Rothel L., Pearse M.et al. Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. Vaccine. 19:2001;4669-4675.
22. Liu W.J., Liu X.S., Zhao K.N., Leggatt G.R., Frazer I.H. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology. 273:2000;374-382.
23. Mateo L., Gardner J., Chen Q., Schmidt C., Down M., Elliott S.L.et al. An HLA-A2 polyepitope vaccine for melanoma immunotherapy. J. Immunol. 163:1999;4058-4063.
24. Woodberry T., Gardner J., Mateo L., Eisen D., Medveczky J., Ramshaw I.A.et al. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8+ cytotoxic T cell epitopes. J. Virol. 73:1999;5320-5325.
25. Thomson S.A., Sherritt M.A., Medveczky J., Elliott S.L., Moss D.J., Fernando G.J.et al. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J. Immunol. 160:1998;1717-1723.
26. Scott P., Trinchieri G. IL-12 as an adjuvant for cell-mediated immunity. Semin. Immunol. 9:1997;285-291.
27. Trinchieri G., Scott P. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. 146:1995;423-431.
28. Heinzel F.P., Schoenhaut D.S., Rerko R.M., Rosser L.E., Gately M.K. Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 177:1993;1505-1509.
29. Sypek J.P., Chung C.L., Mayor S.E.H., Subramanyam J.M., Goldman S.J., Sieburth D.S.et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J. Exp. Med. 177:1993;1797-1802.
30. Afonso L.C.C., Scharton T.M., Vieira L.Q., Wysocka M., Trinchieri G., Scott P. IL-12 functions as an effective adjuvant in a vaccine against Leishmania major by directing the development of leishmanial specific CD4+ Th1 cells. Science. 263:1994;235-237.
31. Stoute J.A., Kester K.E., Krzych U., Wellde B.T., Hall T., White K.et al. Long-term efficacy and immune responses following immunization with the RTS, S malaria vaccine. J. Infect. Dis. 178:1998;1139-1144.
32. Heppner D.G., Gordon D.M., Gross M., Wellde B., Leitner W., Krzych U.et al. Safety, immunogenicity and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J. Infect. Dis. 174:1996;361-366.
33. Gordon D.M., McGovern T.W., Krzych U., Cohen J.C., Schneider I., LaChance R.et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171:1995;1576-1585.
34. Thoelen S., Van Damme P., Mathei C., Leroux-Roels G., Desombere I., Safary A.et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine. 16:1998;708-714.
35. Baldrick P., Richardson D., Wheeler A.W. Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy. Vaccine. 20:2002;737-743.
36. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;498-505.
37. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. In: Powell MF, Newman MJ, editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press, 1995.